Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase III Trial of Hypofractionated Post-Prostatectomy Radiation Therapy (HYPORT) Versus Conventional Post-Prostatectomy Radiation Therapy (COPORT)

NCT03274687 is registered in ClinicalTrials.gov with NRG Oncology as lead sponsor.

NCT NCT03274687
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03274687 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase III Trial of Hypofractionated Post-Prostatectomy Radiation Therapy (HYPORT) Versus Conventional Post-Prostatectomy Radiation Therapy (COPORT)
Lead sponsor
NRG Oncology
Phase
Phase 3
Overall status
Completed
Start date
July 28, 2017
Completion date
December 23, 2025
Enrollment
296 (actual)
Sites
241

Conditions

As the registry lists them; a condition with its own page is linked.

prostate adenocarcinoma, stage i prostate adenocarcinoma ajcc v7, stage ii prostate adenocarcinoma ajcc v7, stage iii prostate adenocarcinoma ajcc v7